Related Experiment Video
Updated: Jan 28, 2026
08:26
Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis
Published on: January 21, 2020
7.2K
Controlled Release Ultrasonic-Coated Drug-Eluting Stent with Multilayers of Chitosan and Curcumin
Jeremia Frandy Apitalau1, Dyah Listyarifah1,2, Adhyatmika -3
1Biomedical Engineering Program, Graduate School, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Recent Advances in Drug Delivery and Formulation
|January 27, 2026
Summary
This study developed a multilayer drug-eluting stent using genipin-crosslinked chitosan and curcumin to prevent initial burst release (IBR). The novel system demonstrates controlled drug release without IBR, reducing restenosis risk.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Polymer Chemistry
Background:
- Commercial drug-eluting stents often exhibit initial burst release (IBR), increasing restenosis risk.
- A multilayer strategy using genipin-crosslinked chitosan and curcumin was employed to overcome IBR limitations.
Purpose of the Study:
- To develop and evaluate a novel multilayer drug-eluting stent system.
- To prevent initial burst release (IBR) and achieve controlled drug delivery.
Main Methods:
- Ultrasonic coating technique used to create uniform layers at varying speeds (7, 8, 9 mm/s).
- Characterization via scanning electron microscopy (SEM).
- Drug release studies analyzed using Korsmeyer-Peppas and Peppas-Sahlin models; analytical method validated with UV-Vis spectrophotometry.
Main Results:
- Release data modeled by Korsmeyer-Peppas indicated Super Case II transport (relaxation/erosion).
- Peppas-Sahlin model showed Fickian diffusion dominating the initial 6-7 days, followed by polymer relaxation.
- Higher speeds (9 mm/s) extended Fickian diffusion duration compared to lower speeds.
Conclusions:
- The multilayer system effectively prevents initial burst release by maintaining matrix integrity.
- Drug release mechanism transitions from diffusion to polymer relaxation, avoiding burst release.
- The system exhibits a controlled-release profile, validated by zero-order model fit.
Related Concept Videos
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
01:10In Vitro Drug Release Testing: Overview, Development and Validation
327
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
327
01:05High-Performance Liquid Chromatography: Elution Process
1.5K
In High-Performance Liquid Chromatography (HPLC), the elution process is critical to the separation of analytes and the quality of chromatographic results. Elution describes how compounds move through the column and separate based on their interactions with the mobile and stationary phases. This process determines the resolution, peak shape, and retention times in the chromatogram, which are essential for identifying and quantifying components in complex mixtures. Understanding the elution...
1.5K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
886
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
886
01:03Drug Control Governance: Regulatory Bodies and Their Impact
534
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
534
01:12Clathrin Coated Vesicles
9.3K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
9.3K